헤더 로고

• All
• March 26 (Thu)
• March 27 (Fri)
• March 28 (Sat)

Day 2: March 27 (Fri)

• Multi-Omic Precision Medicine including Functional Drug Screening to Optimize Treatment for Acute Myeloid Leukemia Pamela S. Becker
  City of Hope, USA CV Abstract
• Novel Immunotherapeutic Strategies: Preclinical Insights Ji Eun Jang
  Yonsei University College of Medicine, Korea CV Abstract
• Developing Next-Generation Cell Therapy Approaches for AML Paulina Velasquez
  St. Jude Children’s Research Hospital, USA CV Abstract
• Emerging Ex-vivo Drug Sensitivity Platforms Daehun Kwag
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 27 (Fri)

• Microbiome-Driven Precision Medicine in CAR-T Cell Therapy in Hematology Christoph K. Stein-Thoeringer
  University Clinic Tübingen, Germany CV Abstract
• Gut Microbiome as a Predictive Biomarker and Emerging Intervention Target in DLBCL Woorim Kang
  Kangwon National University, Korea CV Abstract
• Microbiome in Allogeneic Hematopoietic Cell Transplantation & Immunotherapy Jonathan U. Peled
  Memorial Sloan Kettering Cancer Center, USA CV Abstract

Day 2: March 27 (Fri)

• A Personalized Approach to Immune Therapies for Cancer: One Drug, One Patient Larry W. Kwak
  City of Hope, USA CV Abstract
• Paradigm Shift in the Treatment of Diffuse Large B-cell Lymphoma: The Era of Bispecific Antibodies Won Seog Kim
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Toward a Paradigm Shift in Personalized Therapies for DLBCL Using Liquid Biopsies Ash A. Alizadeh
  Stanford University, USA CV Abstract

Day 2: March 27 (Fri)

• Iron Deficiency & Iron Metabolism Jeong-Ok Lee
  Seoul National University College of Medicine, Korea CV Abstract
• Hereditary Hemolytic Anemia Heewon Chueh
  Inje University College of Medicine, Korea CV Abstract
• Cold Agglutinin Disease Dae-Ho Choi
  Sungkyunkwan University School of Medicine, Korea CV Abstract

Day 2: March 27 (Fri)

• The Past, Present and Future of Hematopoietic Stem Cell Gene Therapies Cynthia E. Dunbar
  National Institutes of Health, USA CV Abstract

Day 2: March 27 (Fri)

• Triple Targeting in Myelofibrosis with Momelotinib: Integrated Therapeutic Approach via JAK1/2 and ACVR1 Inhibition Sung-Eun Lee
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 27 (Fri)

• Clinical Evidence of Romiplostim in Aplastic Anemia: Korean Expert Recommendations Silvia Park
  College of Medicine, The Catholic University of Korea, Korea CV Abstract

Day 2: March 27 (Fri)

• Daratumumab in the Emerging Landscape of Functional High-Risk Multiple Myeloma Andrew Spencer
  Alfred Hospital, Australia CV Abstract

Day 2: March 27 (Fri)

• Early CAR-T Intervention in DLBCL: Clinical Advances and Real-World Effectiveness of Axi-cel Mark Dowling
  Peter MacCallum Cancer Centre, Australia CV Abstract

Day 2: March 27 (Fri)

• How to Optimize CML Treatment in 2026: ELN 2025 and Molecular Guidance Elias Jabbour
  MD Anderson Cancer Center, USA CV Abstract

Day 2: March 27 (Fri)

• Operations to Evidence: How Registry Data from CAR T-cell Therapy Inform Practice Change Jürgen Kuball
  University Medical Center Utrecht, The Netherlands CV Abstract
• Korean CAR T-cell Registry: Inauguration and the Current Status of CAR T-cell Therapy in Korea Ji Hyun Lee
  Dong-A University College of Medicine, Korea CV Abstract
• CAR T-cell Therapy for Primary and Secondary CNS Lymphomas Andrés J. M. Ferreri
  University Vita-Salute San Raffaele, Italy CV Abstract
• CAR T-cell Therapy in Primary and Secondary CNS Lymphomas in Korea Hyungwoo Cho
  Asan Medical Center, University of Ulsan College of Medicine, Korea CV Abstract

Day 2: March 27 (Fri)

• Genomics and Transplant Strategies in Pediatric Myeloid Malignancies Jae Wook Lee
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• Virus-Specific and Next-Generation T-cell Therapy in Pediatric Hematologic Malignancy Catherine M. Bollard
  Children’s National Hospital and The George Washington University, USA CV Abstract
• Cancer Survivorship after the Cure of Childhood Blood Cancers: Risk Based Surveillance Sharon M. Castellino
  Emory University School of Medicine, USA CV Abstract

Day 2: March 27 (Fri)

• Stem Cells in Human AML Ravindra Majeti
  Stanford University, USA CV Abstract
• Evolving Frontiers in Targeted Therapy: Menin Inhibition in AML Eytan M. Stein
  Memorial Sloan Kettering Cancer Center, USA CV Abstract
• HMA + Venetoclax + Targeted Agents: Clinical Evidence and Future of Triplet Therapy in AML Tapan Kadia
  The University of Texas MD Anderson Cancer Center, USA CV

Day 2: March 27 (Fri)

• Real-World Effectiveness of Immunotherapy in Hematologic Malignancies: Evidence from Big Data Sung-Soo Park
  College of Medicine, The Catholic University of Korea, Korea CV Abstract
• Digital Healthcare Innovation: Real-World Applications of Big Data and AI Yoon Sup Choi
  Digital Healthcare Partners (DHP), Korea CV
• Wise Hematology Life: Practical Integration of Large Language Models and Agentic AI into Clinical Research Jeong-Moo Lee
  Ewha Womans University College of Medicine, Korea CV Abstract

Day 2: March 27 (Fri)

• Real World Long Term TPO-RA: Sustaining Remission or Time to Stop? Nichola Cooper
  Imperial College Health Care NHS Trust, UK CV Abstract
• A New Chapter in ITP Management - Updated Trials Jun Ho Jang
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Caplacizumab and the Changing Landscape of TTP Management Shruti Chaturvedi
  Johns Hopkins University School of Medicine, USA CV

Day 2: March 27 (Fri)

• AL Amyloidosis: A Comprehensive Update from Fundamentals to Emerging Therapies Efstathios Kastritis
  National and Kapodistrian University of Athens, Greece CV Abstract
• Monoclonal Gammopathy and the Kidney: A Comprehensive Approach to MGRS Nelson Leung
  Mayo Clinic, USA CV Abstract
• Novel Biological and Clinical Insights into POEMS Syndrome: Pathophysiology and Real-World Treatment Outcomes from Japan Emiko Sakaida
  Chiba University Hospital, Japan CV Abstract

Day 2: March 27 (Fri)

• CRS and ICANS: Early Detection and Personalized Management Jinchul Kim
  Inha University College of Medicine, Korea CV Abstract
• Prolonged Cytopenia after TCEs: Mechanisms, Biomarkers, and Risk Stratification Sang Eun Yoon
  Sungkyunkwan University School of Medicine, Korea CV Abstract
• Preventing Infections in TCEs: Risk Stratification and Prophylaxis Ja Min Byun
  Seoul National University College of Medicine, Korea CV Abstract